[cbdagency]

I have launched a crowd-funding campaign for clinical trials of cannabis to treat ADHD at https://www.indiegogo.com/projects/c...-to-treat-adhd. The only way for most ADHD sufferers around the world to legally access this vital medicine is for a definitive study of efficacy to be done. Until then patients will continue to be denied their basic human right to happy, healthy lives by doctors and governments claiming that insufficient evidence exists. Lets give them the evidence... please consider giving a donation, and please share the campaign page with your networks as this is an important cause that effects many lives. Together we can make a difference!

[Altered Moment]

I whole heartedly support this type of research. Big pharma won't study it as you can't patent naturally occurring substances. I imagine we will see more research though. The ancedotal evidence with kids and seizures is quite compelling. Dr. Sanjy Gupta did a special on CNN last night on it.

This is a very real scientific study. If it is published in Nature it is a respected scientific study. It is hard to read.

Translational Psychiatry - Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation

Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation

Abstract
Stress is a major risk factor for the development of mood and anxiety disorders; elucidation of novel approaches to mitigate the deleterious effects of stress could have broad clinical applications. Pharmacological augmentation of central endogenous cannabinoid (eCB) signaling may be an effective therapeutic strategy to mitigate the adverse behavioral and physiological consequences of stress. Here we show that acute foot-shock stress induces a transient anxiety state measured 24 h later using the light–dark box assay and novelty-induced hypophagia test. Acute pharmacological inhibition of the anandamide-degrading enzyme, fatty acid amide hydrolase (FAAH), reverses the stress-induced anxiety state in a cannabinoid receptor-dependent manner. FAAH inhibition does not significantly affect anxiety-like behaviors in non-stressed mice. Moreover, whole brain anandamide levels are reduced 24 h after acute foot-shock stress and are negatively correlated with anxiety-like behavioral measures in the light–dark box test. These data indicate that central anandamide levels predict acute stress-induced anxiety, and that reversal of stress-induced anandamide deficiency is a key mechanism subserving the therapeutic effects of FAAH inhibition. These studies provide further support that eCB-augmentation is a viable pharmacological strategy for the treatment of stress-related neuropsychiatric disorders.

Another respected scientific study.

http://www.nel.edu/pdf_/25_12/NEL251204R02_Russo_.pdf

Clinical Endocannabinoid Deficiency (CECD):
Can this Concept Explain Therapeutic Benefits of Cannabis in
Migraine, Fibromyalgia, Irritable Bowel Syndrome and other
Treatment-Resistant Conditions?

I am sure there are more. It is being studied. Exactly which cannabinoid may be beneficial I am not clear on. It seems with seizures it is CBD and not THC.